HC Wainwright Cuts PolyPid (NASDAQ:PYPD) Price Target to $11.00

PolyPid (NASDAQ:PYPD) had its target price reduced by HC Wainwright from $14.00 to $11.00 in a research report report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Craig Hallum started coverage on PolyPid in a report on Monday, November 4th. They set a “buy” rating and a $10.00 target price on the stock.

PolyPid Stock Up 1.4 %

NASDAQ:PYPD opened at $2.89 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17. PolyPid has a 12-month low of $2.37 and a 12-month high of $9.20. The stock’s fifty day simple moving average is $3.24 and its 200-day simple moving average is $3.51. The firm has a market capitalization of $13.86 million, a P/E ratio of -0.37 and a beta of 1.33.

Institutional Trading of PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC acquired a new stake in PolyPid Ltd. (NASDAQ:PYPD) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned 2.89% of PolyPid as of its most recent filing with the SEC. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.